New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For MDT;COV;INTC;BSX;VRTX;JNJ From The Last 14 Days
Check below for free stories on MDT;COV;INTC;BSX;VRTX;JNJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | all recent news | >>
April 16, 2014
17:53 EDTMDTEdwards says not looking for complete ban of Medtronic valve, Bloomberg says
Subscribe for More Information
15:39 EDTBSXBoston Scientific CRT-D approval neutral for St. Jude, says Wells Fargo
Subscribe for More Information
10:51 EDTINTCOptions with decreasing implied volatility: DLLR FAST INTC
Subscribe for More Information
10:00 EDTINTCOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:20 EDTINTCIntel results, guidance were good, says Wells Fargo
Wells Fargo says that Intel's gross margin for its March quarter beat expectations, while the company guided for sequential revenue growth for its June quarter. The firm thinks the company is making some headway in penetrating the tablet market, and keeps an Outperform rating on the shares.
07:43 EDTINTCIntel price target raised to $35 from $32 at Jefferies
Subscribe for More Information
07:38 EDTJNJJohnson & Johnson reported very strong Q1 results, says Bernstein
Subscribe for More Information
06:06 EDTINTCIntel price target raised to $30 from $28 at Deutsche Bank
Deutsche Bank raised its price target for Intel shares to $30 citing the company's "solid" Q1 results. The firm views Intel's second half guidance as conservative and keeps a Buy rating on the stock.
05:43 EDTINTCIntel downgraded to Neutral from Buy at B. Riley
Subscribe for More Information
April 15, 2014
18:58 EDTINTCOn The Fly: After Hours Movers
Subscribe for More Information
18:48 EDTINTCIntel CFO says plans to capitalize on the Internet of Things
Subscribe for More Information
17:51 EDTINTCIntel says 'squarely on track' to ship 40M tablet SOC's in 2014
Subscribe for More Information
17:38 EDTJNJJohnson & Johnson stock looks attractive, Barron's says
Johnson & Johnson stock looks attractive and there's still time to buy in, Barron's contends in its "Barron's Take" column. The company can still deliver strong returns, the paper adds. Reference Link
16:47 EDTBSXBoston Scientific announces FDA approval for defibrillators
Subscribe for More Information
16:30 EDTINTCIntel CFO sees gross margins 'in low 60's' in back half of 2014
Says making investments in mobile space. Says companies are buying new PC's to replace older installed base. Intel CFO Stacy Smith is speaking on CNBC.
16:22 EDTJNJOn The Fly: Closing Wrap
Subscribe for More Information
16:15 EDTINTCIntel reports Q1 PC Client Group revenue $7.9B, down 8% sequentially
Subscribe for More Information
16:09 EDTINTCIntel rises to new 52-week high after results, first look
Subscribe for More Information
16:07 EDTINTCIntel CEO says saw solid growth in the data center in Q1
"In the first quarter we saw solid growth in the data center, signs of improvement in the PC business, and we shipped 5 million tablet processors, making strong progress on our goal of 40 million tablets for 2014," said Intel CEO Brian Krzanich. "Additionally, we demonstrated our further commitment to grow in the enterprise with a strategic technology and business collaboration with Cloudera, we introduced our second-generation LTE platform with CAT6 and other advanced features, and we shipped our first Quark products for the Internet of Things."
16:06 EDTINTCIntel sees Q2 gross margin 63%, plus or minus a couple of percentage points
Subscribe for More Information
16:05 EDTINTCIntel sees FY14 revenue approximately flat, consensus $53.15B
Sees FY14 gross margin 61%, plus or minus a few percentage points. Sees FY14 CapEx $11B, plus or minus $500M.
16:04 EDTINTCIntel reports Q1 gross margin 59.7%
Subscribe for More Information
16:03 EDTINTCIntel sees Q2 revenue $13B, plus or minus $500M, consensus $12.96B
Subscribe for More Information
16:02 EDTINTCIntel reports Q1 EPS 38c, consensus 37c
Reports Q1 revenue $12.8B, consensus $12.81B.
15:19 EDTINTCNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Intel (INTC), consensus 37c; Yahoo (YHOO), consensus 37c; CSX (CSX), consensus 37c; Linear Technology (LLTC), consensus 48c; Wintrust Financial (WTFC), consensus 67c.
15:10 EDTINTCIntel April 26 straddle priced for 4% move into Q1
Subscribe for More Information
14:25 EDTINTCIntel April option elevated into Q1 and outlook
Intel April call option implied volatility is at 41, May is at 21, June and October is at 19; compared to its 26-week average of 21 according to Track Data, suggesting large near term price movement into the release of Q1 results today after the market close.
13:49 EDTINTCEarnings Preview: Analysts optimistic on Intel ahead of Q1 report
Subscribe for More Information
12:58 EDTJNJOn The Fly: Midday Wrap
Subscribe for More Information
11:53 EDTBSXVascular Solutions: Injunction against Boston Scientific's Guidezilla vacated
Subscribe for More Information
10:23 EDTJNJOptions with decreasing implied volatility: FDO JNJ FAST EPB
Subscribe for More Information
09:23 EDTBSX, COVBarclays medical supplies/devices analysts hold analyst/industry conference call
Subscribe for More Information
09:16 EDTJNJOn The Fly: Pre-market Movers
Subscribe for More Information
09:11 EDTJNJJohnson & Johnson says has implemented some cost reductions in MD&D sector
Says has implemented some cost reductions, combined some businesses in the Medical Devices & Diagnostics sector to better compete in the current marketplace.
08:56 EDTJNJJohnson & Johnson sees FY net interest expense $400M-$500M
Subscribe for More Information
08:19 EDTJNJJohnson & Johnson sees deal to sell K-Y brand to Reckitt closing mid-year
Sees sees deal to sell K-Y brand to Reckitt Benckiser (RBGPF) closing mid-year. Says offer from Carlyle Group (CG) to acquire Ortho-Clinical Diagnostics expected to close mid-year. Comments from slides that will be presented on the Q1 earnings conference call.
07:49 EDTJNJJohnson & Johnson reports Q1 Domestic sales up 2.2%; Intl sales up 4.5%
Subscribe for More Information
07:47 EDTJNJJohnson & Johnson raises FY14 EPS to $5.80-$5.90, consensus $5.83
Subscribe for More Information
07:46 EDTJNJJohnson & Johnson reports Q1 adjusted EPS $1.54, consensus $1.48
Reports Q1 revenue $18.1B, consensus $18.0B
06:32 EDTJNJPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
April 14, 2014
16:24 EDTMDTOn The Fly: Closing Wrap
Subscribe for More Information
15:17 EDTJNJNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Johnson & Johnson (JNJ), consensus $1.48; Coca-Cola (KO), consensus 44c; Charles Schwab (SCHW), consensus 22c; Northern Trust (NTRS), consensus 78c; Comerica (CMA), consensus 72c; Westamerica (WABC), consensus 58c; Comverse (CNSI), consensus 49c; Pep Boys (PBY), consensus 5c.
13:25 EDTJNJEarnings Preview: J&J looking for another strong performance in pharmaceuticals
Subscribe for More Information
12:26 EDTMDTOn The Fly: Midday Wrap
Subscribe for More Information
10:51 EDTMDTEdwards up after court limits sale of Medtronic's CoreValve in U.S.
Subscribe for More Information
10:02 EDTJNJ, MDTOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
10:02 EDTBSXOn The Fly: Analyst Upgrade Summary
Acorda Therapeutics (ACOR) upgraded to Outperform from Market Perform at FBR Capital... Allegheny Technologies (ATI) upgraded to Neutral from Underperform at Sterne Agee... BP (BP) upgraded to Buy from Hold at Canaccord... Bloomin' Brands (BLMN) upgraded to Buy from Hold at Deutsche Bank... Boardwalk Pipeline (BWP) upgraded to Neutral from Underperform at BofA/Merrill... Boston Scientific (BSX) upgraded at BofA/Merrill... Charles Schwab (SCHW) upgraded to Buy from Neutral at UBS... Citigroup (C) upgraded to Hold from Sell at Rafferty Capital... Community Health (CYH) upgraded to Outperform from Perform at Oppenheimer... Eaton Vance (EV) upgraded to Neutral from Sell at Citigroup... Eli Lilly (LLY) upgraded to Hold from Underperform at Jefferies... F5 Networks (FFIV) upgraded to Buy from Hold at Stifel... HeartWare (HTWR) upgraded to Buy from Neutral at BTIG... Heartland Payment (HPY) upgraded to Hold from Sell at Stifel... Hyatt Hotels (H) upgraded to Outperform from Market Perform at FBR Capital... MasterCard (MA) upgraded to Outperform from Neutral at RW Baird... McDermott (MDR) upgraded to Neutral from Underweight at HSBC... Palo Alto (PANW) upgraded to Overweight at Stephens... PetroChina (PTR) upgraded to Neutral from Underperform at Credit Suisse... Seagate (STX) upgraded to Buy from Hold at Argus... Sensata (ST) upgraded to Buy from Neutral at Citigroup... Stryker (SYK) upgraded to Neutral from Reduce at SunTrust... TD Ameritrade (AMTD) upgraded to Buy from Neutral at UBS... TTM Technologies (TTMI) upgraded to Buy from Hold at Stifel... Transocean (RIG) upgraded to Hold from Sell at Deutsche Bank... VMware (VMW) upgraded to Outperform from Underperform at CLSA... Visa (V) upgraded to Outperform from Neutral at RW Baird... Yahoo (YHOO) upgraded to Buy from Neutral at SunTrust... Zimmer (ZMH) upgraded to Neutral from Reduce at SunTrust... bebe stores (BEBE) upgraded to Buy from Neutral at Janney Capital.
09:00 EDTMDTMedtronic falls 5.4%
Medtronic is down 5.4%, or $3.20, to $56.00
08:59 EDTMDTOn The Fly: Pre-market Movers
Subscribe for More Information
08:05 EDTCOVCovidien announces FDA 510(k) clearance for Kangaroo feeding tube
Subscribe for More Information
07:39 EDTMDTEdwards Lifesciences upgraded to Buy from Fair Value at CRT Capital
Subscribe for More Information
06:44 EDTBSXBoston Scientific upgraded at BofA/Merrill
As previously reported, BofA/Merrill upgraded Boston Scientific to Buy from Neutral. The firm upgraded shares given increased confidence in the pipeline, opportunities to increase margin, valuation, and expectations the FDA will approve the LAA product this year. Price target raised to $16.
06:22 EDTMDTMedtronic downgraded to Neutral from Overweight at JPMorgan
Subscribe for More Information
06:21 EDTMDTEdwards Lifesciences upgraded to Neutral from Underweight at JPMorgan
Subscribe for More Information
06:18 EDTBSXBoston Scientific upgraded to Buy from Neutral at BofA/Merrill
Price target is $16.
06:11 EDTINTCIntel works with HzO to enhance water resistance in products, DigiTimes says
Subscribe for More Information
06:04 EDTINTCIntel promoting pricing strategy for tablet CPUs in China, DigiTimes reports
Intel is aggressively promoting a pricing strategy to increase sales of its tablet-use processors in China, reports DigiTimes. According to industry sources, prices of mainstream quad-core tablet CPUs have dropped to below $5 and the number of Intel-based tablets is likely to expand in proportion. Reference Link
05:56 EDTJNJJohnson & Johnson downgraded to Hold from Buy at Jefferies
Jefferies downgraded its rating on Johnson & Johnson (JNJ) to Hold citing the recent outperformance of shares. The firm keeps a $105 price target for the stock.
April 13, 2014
15:10 EDTMDTMedtronic says CoreValve ruling has no impact outside U.S.
Subscribe for More Information
April 12, 2014
19:50 EDTMDTEdwards says court limits sale of Medtronic CoreValve system in U.S.
Edwards Lifesciences (EW) announced that the U.S. District Court for the District of Delaware granted a preliminary injunction limiting the sale of Medtronic's (MDT) CoreValve system in the United States. The court ordered the injunction to go into effect in seven business days. The hearing related to a federal jury decision in 2010 that CoreValve willfully infringes Edwards' U.S. Andersen transcatheter aortic valve replacement patent. At the conclusion of the hearing, Chief Judge Gregory Sleet ordered Edwards and Medtronic to confer on what instances the CoreValve device could continue to be used in the treatment of U.S. patients at centers currently trained on CoreValve. There is a large body of evidence demonstrating the safety and performance of the Edwards SAPIEN valves, and the company remains committed to ensuring patients have appropriate access to transcatheter therapy. This case was initiated by Edwards in 2008. On April 1, 2010, a federal jury found Medtronic willfully infringed Edwards' U.S. Andersen patent and awarded damages. In Nov. 2012, the U.S. Court of Appeals for the Federal Circuit affirmed the jury decision; in Oct. 2013, the U.S. Supreme Court declined to hear Medtronic's appeal. The patent involved in this suit is part of the Andersen family of patents. The U.S. Andersen patent was issued in 1995. A petition has been filed with the U.S. Patent and Trademark Office to extend this patent into early 2016. In a separate case, a federal jury in January found that Medtronic CoreValve had willfully infringed Edwards' U.S. Cribier transcatheter heart valve patent, and awarded damages to Edwards in that trial.
April 11, 2014
18:44 EDTJNJJ&J halting development of Botox competitor, WSJ says
Subscribe for More Information
12:42 EDTINTCOn The Fly: Analyst Initiation Summary
ASML (ASML) initiated with a Cautious at ISI Group... Analog Devices (ADI) initiated with a Buy at ISI Group... Applied Materials (AMAT) initiated with a Strong Buy at ISI Group... Aruba Networks (ARUN) initiated with a Buy at SunTrust... Broadcom (BRCM) initiated with a Neutral at ISI Group... CSX (CSX) initiated with an Outperform at Macquarie... Cisco (CSCO) initiated with a Buy at SunTrust... F5 Networks (FFIV) initiated with a Neutral at SunTrust... Genesee & Wyoming (GWR) initiated with a Neutral at Macquarie... Intel (INTC) initiated with a Neutral at ISI Group... Juniper (JNPR) initiated with a Buy at SunTrust... KLA-Tencor (KLAC) initiated with a Neutral at ISI Group... Lam Research (LRCX) initiated with a Strong Buy at ISI Group... Linear Technology (LLTC) initiated with a Cautious at ISI Group... Maxim Integrated (MXIM) initiated with a Neutral at ISI Group... Micron (MU) initiated with a Strong Buy at ISI Group... NVIDIA (NVDA) initiated with a Neutral at ISI Group... NXP Semiconductors (NXPI) initiated with a Strong Buy at ISI Group... Qualcomm (QCOM) initiated with a Strong Buy at ISI Group... Riverbed (RVBD) initiated with a Neutral at SunTrust... SanDisk (SNDK) initiated with a Neutral at ISI Group... Teradyne (TER) initiated with a Buy at ISI Group... Texas Instruments (TXN) initiated with a Neutral at ISI Group... Trulia (TRLA) initiated with a Neutral at Susquehanna... Union Pacific (UNP) initiated with a Neutral at Macquarie... Zillow (Z) initiated with a Positive at Susquehanna... Flamel Technologies (FLML) initiated with a Buy at Roth Capital... Parker Drilling (PKD) initiated with an Accumulate at Tudor Pickering.
11:42 EDTCOVCovidien liability from recall appears limited, says Brean Capital
Subscribe for More Information
08:10 EDTCOVCovidien implements voluntary recall of devices
Subscribe for More Information
07:18 EDTINTCJefferies a buyer of Intel shares ahead of Q1 results
Subscribe for More Information
April 10, 2014
19:10 EDTMDTMedtronic confirms FDA approval for expanded indications
Subscribe for More Information
18:34 EDTBSXBoston Scientific enrolls first patient in registry for evaluating Vercise DBS
Subscribe for More Information
16:32 EDTMDTMedtronic gets FDA approval for revised labeling application
The U.S. FDA approved an application from Medtronic for revised labeling for two cardiac resynchronization pacemakers and eight cardiac resynchronization defibrillators, expanding the indication for use to patients with atrioventricular block and less severe heart failure. The FDA previously approved these devices for patients with more severe heart failure as evaluated by their physician using specific criteria. The new approved use includes patients with less severe heart failure, but who are already indicated to receive RV pacing. With the new indication, these patients will be eligible to receive a device that will pace both sides of their heart instead of just the right. Reference Link
16:20 EDTINTCIntel initiated with a Neutral at ISI Group
Target $26.
06:13 EDTINTCIntel to launch Haswell Refresh CPUs, 9-series chipsets in May, DigiTimes says
Subscribe for More Information
April 9, 2014
07:23 EDTJNJEuropean Association for the Study of the Liver to hold annual meeting
Subscribe for More Information
07:09 EDTJNJJohnson & Johnson outlook positive into Q1 results, says Bernstein
Bernstein expects Johnson & Johnson's Q1 EPS to come in slightly above the consensus estimate, with strength in pharmaceuticals more than offsetting lackluster Medical Devices & Diagnostics growth, according to the firm. Bernstein keeps an Outperform rating on the stock.
07:00 EDTINTCBofA, Intel fire 3K workers, leaving Costa Rica shocked, Bloomberg says
Subscribe for More Information
06:20 EDTINTCIntel plans 1,500 job cuts in Cosa Rica, WSJ reports
Intel is planning to lay off about 1,500 employees in Costa Rica, the Wall Street Journal reports. The company will move longtime assembly and test operations in the country to three locations in Asia. The latest job cuts reduce Intel's workforce by about 1.4%. Reference Link
April 8, 2014
08:08 EDTINTCCost to Apple, Google, Intel, of 'no-poaching' deal may be high, DealBook says
Some of the of the biggest names in tech, including Apple (AAPL), Google (GOOG), Intel (INTC)and Adobe (ADBE), are at the center of a class-action suit that seeks $9B as compensation for employees who contend the tech giants colluded to prevent their employees from being hired at rivals, reported The New York Times' DealBook. Reference Link
07:26 EDTCOV, JNJ, MDTElsevier Business Intelligence to hold a conference
Subscribe for More Information
April 7, 2014
18:01 EDTBSXBoston Scientific gets FDA, CE Mark clearance for Expect Slimline Needle
Boston Scientific announced it has received clearance from the U.S. FDA and CE Mark approval in Europe for the Expect Slimline Needle, which is now globally available for Endoscopic Ultrasound-Fine Needle Aspiration procedures. The Expect Slimline Needle is on contract with four leading group purchasing organizations.
10:00 EDTINTCOn The Fly: Analyst Upgrade Summary
Agios Pharmaceuticals (AGIO) upgraded to Overweight from Neutral at JPMorgan... Alcoa (AA) upgraded to Hold from Sell at Deutsche Bank... Align Technology (ALGN) upgraded to Outperform from Market Perform at Barrington... Analog Devices (ADI) upgraded to Neutral from Sell at Goldman... B&G Foods (BGS) upgraded to Outperform from Sector Perform at RBC Capital... Citigroup (C) upgraded to Neutral from Underweight at HSBC... Intel (INTC) upgraded to Outperform from Sector Perform at Pacific Crest... JetBlue (JBLU) upgraded to Neutral from Sell at Goldman... Kindred Healthcare (KND) upgraded to Outperform from Sector Perform at RBC Capital... Lennox (LII) upgraded to Outperform from Market Perform at Wells Fargo... Newmont Mining (NEM) upgraded to Hold from Sell at Deutsche Bank... PBF Energy (PBF) upgraded to Buy from Neutral at Citigroup... Renasant (RNST) upgraded to Outperform from Market Perform at Raymond James... Select Medical (SEM) upgraded to Outperform from Sector Perform at RBC Capital... Ultra Petroleum (UPL) upgraded to Outperform from Market Perform at Raymond James... Under Armour (UA) upgraded to Buy from Neutral at Sterne Agee... Hercules Technology (HTGC) upgraded to Buy from Hold at Sandler ONeill... Standard Pacific (SPF) upgraded to Outperform from Market Perform at Raymond James... Yelp (YELP) upgraded to Outperform from Perform at Oppenheimer... Netflix (NFLX) upgraded to Outperform from Perform at Oppenheimer... Pandora (P) upgraded to Outperform from Neutral at Wedbush.
07:58 EDTMDTMedtronic data positive for C.R. Bard, says Barclays
Barclays said Medtronic's (MDT) better than expected drug coated balloon data could have a positive class effect that benefits C.R. Bard (BCR). The firm reiterates its Overweight rating C.R. Bard and raised its price target to $165 from $160. Note that BofA/Merrill downgraded C.R. Bard to Neutral from Buy following the Medtronic's news.
07:38 EDTMDTMedtronic data should lead to approval of drug-coated balloon, says Wells Fargo
Subscribe for More Information
05:55 EDTINTCIntel upgraded to Outperform from Sector Perform at Pacific Crest
Pacific Crest upgraded its rating on Intel (INTC) shares to Outperform with a $31 price target citing improving corporate PC demand and expectations the company's Grantley server platform will drive spending at traditional IT customers in 2015. Shares of Intel closed Friday down 25c to $26.16.
April 4, 2014
16:00 EDTINTCOptions Update; April 4, 2014
iPath S&P 500 VIX Short-Term Futures up 89c to 41.88. Option volume leaders: AAPL C P NFLX LNG BAC INTC TSLA TWTR according to Track Data.
April 3, 2014
16:16 EDTINTCGlobalfoundries in lead to buy IBM chip plants, TSMC out of talks, WSJ says
IBM (IBM) has held talks with Globalfoundries, Intel (INTC) and Taiwan Semiconductor (TSM) regarding its semiconductor manufacturing operations, and Globalfoundries appears to be in the lead as the most likely potential buyer, according to The Wall Street Journal, citing people familiar with the matter. IBM initially asked for more than $2B and bids have come in "north of $1B," the report noted, adding that Intel is still involved, but TSMC has dropped out of the talks. Reference Link
16:00 EDTINTCOptions Update; April 3, 2014
Subscribe for More Information
15:49 EDTINTCGlobalfoundries in lead to buy IBM chip plants, TSMC out of talks, DJ says
IBM (IBM) also held talks with Intel (INTC), according to Dow Jones, citing sources.
10:01 EDTINTCIntel climbs following upbeat note from analyst
Subscribe for More Information
10:00 EDTINTCOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
April 2, 2014
16:09 EDTINTCIntel upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray upgraded Intel to Overweight from Neutral after assuming coverage of the stock and raised its price target for shares to $30 from $23. Piper expects the PC market stabilization to continue in 2014 and believes Intel is positioned longer term to benefit from data center market growth.
15:00 EDTCOVCovidien management to meet with Piper Jaffray
Subscribe for More Information
09:36 EDTMDTMedtronic has a conference call hosted by JPMorgan
JPMorgan Analyst Weinstein will host a conference call with CEO Omar Ishrak on April 3 at 10 am.
08:40 EDTJNJ, COVPiper Jaffray to hold booth tours
Booth Tours at SAGES Annual Meeting will be held in Salt Lake City, Utah on April 2-3.
08:31 EDTBSX, COVSociety of American Gastrointestinal & Endoscopic Surgeons holds annual meeting
2014 Annual Meeting of SAGES is being held in Salt Lake City, Utah on April 2-5.
06:08 EDTINTCIntel setting up $100M fund for China, WSJ reports
Intel's venture capital arm will establish a $100M fund to help accelerate the creation of new devices that use its chips, the Wall Street Journal reports, citing comments made at an event for developers. The company is also setting up an innovation center in Shenzhen, China. Reference Link
05:23 EDTBSXBoston Scientific reports favorable results in MADIT-CRT study
Boston Scientific reported favorable results in studies related to cardiac resynchronization therapy, or CRT, platinum chromium stent platforms and transcatheter aortic valve replacement, or TAVR. Boston Scientific announced significant findings from the continued analysis of the landmark MADIT-CRT study, demonstrating a significant and sustained survival benefit in the indicated population. The long-term results demonstrated a 41% relative reduction in the risk of death in patients who received a Boston Scientific defibrillator with CRT compared to patients who received a defibrillator alone. In addition to the mortality benefit, the results demonstrate that these patients experienced a 62% relative reduction in the risk of experiencing a first heart failure event when compared to patients who didn't receive CRT therapy. Boston Scientific released new data that continue to reinforce the advantages of platinum chromium stents. The trial compared the safety and effectiveness of the Boston Scientific Platinum Chromium Everolimus-Eluting Stent System, or PtCr EES, to the Abbott Laboratories Cobalt Chromium Everolimus-Eluting Stent System, or CoCr EES. The results show low event rates out to four years with PtCr EES confirming excellent long-term performance. At four years, the PtCr EES also continued to demonstrate advantages over the CoCr EES. The Boston Scientific Lotus Valve System advanced TAVR technology continued to demonstrate impressive performance at three months.
<< 1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use